Skip to main content
Karolinska Development logo

Karolinska Development — Investor Relations & Filings

Ticker · KDEV ISIN · SE0002190926 LEI · 54930011ZA52NKO5W681 ST Financial and insurance activities
Open in API
Filings indexed 761 across all filing types
Latest filing 2019-08-16 Capital/Financing Update
Country SE Sweden
Listing ST KDEV

About Karolinska Development

https://www.karolinskadevelopment.com/en

Karolinska Development is an investment company specializing in the life sciences sector. It identifies, finances, and supports the creation and growth of companies developing innovative medical technologies and pharmaceuticals. The firm manages a diversified portfolio of biotechnology and medtech ventures, often originating from academic research, with the goal of developing ground-breaking treatments for severe diseases. Karolinska Development leverages its team's expertise in research, development, and commercialization to guide its portfolio companies, providing both capital and strategic support to advance innovations toward the market.

Recent filings

Filing Released Lang Actions
Karolinska Development förlänger teckningsperioden i den riktade nyemissionen till Bolagets konvertibelinnehavare
Capital/Financing Update Classification · 1% confidence The document is a press release dated August 16, 2019, announcing an extension of the subscription period for a directed new share issue (nyemission) aimed at convertible bondholders. This action directly relates to the company's capital structure and fundraising activities. Based on the definitions, the most appropriate category is 'Capital/Financing Update' (CAP), as it details changes related to issuing new shares/securities as part of a financing event. Although it involves share issuance, the primary focus is the financing mechanism (convertible debt conversion) and the extension of the terms, making CAP more specific than SHA (Share Issue/Capital Change) or POS (Transaction in Own Shares). The document is a formal announcement, not a full report or a general regulatory filing fallback.
2019-08-16 Swedish
Karolinska Development extends the subscription period in the directed share issue to holders of the Company’s convertible loan
Share Issue/Capital Change Classification · 1% confidence The document is a press release dated August 16, 2019, announcing an extension to the subscription period for a directed share issue related to a convertible loan. This action directly concerns the company's capital structure and fundraising activities. Based on the definitions, this fits best under 'Capital/Financing Update' (CAP), as it details changes and extensions related to a specific financing instrument (convertible loan set-off via share issue). It is not a full annual report (10-K), an earnings release (ER), or a general regulatory filing (RNS), but a specific announcement about capital structure modification.
2019-08-16 English
Karolinska Development's portfolio company Aprea Therapeutics appoints Scott Coiante as CFO
Board/Management Information Classification · 1% confidence The document is a press release announcing the appointment of a new Chief Financial Officer (Scott Coiante) at a portfolio company (Aprea Therapeutics). According to the filing definitions, announcements regarding changes in senior management fall under the 'MANG' category. Although the document includes an 'Attachment' link, the primary content is the announcement of the management change itself, not merely a notification of a report publication.
2019-08-05 English
Karolinska Development's portfolio company Aprea Therapeutics appoints Scott Coiante as CFO
Board/Management Information Classification · 1% confidence The document is a press release announcing the appointment of a new Chief Financial Officer (Scott Coiante) at a portfolio company (Aprea Therapeutics). According to the filing definitions, announcements regarding changes in senior management fall under the 'MANG' category. Although the document includes an 'Attachment' link, the primary content is the announcement of the management change itself, not merely a notification of a report publication.
2019-08-05 English
Karolinska Development's portfolio company Aprea Therapeutics appoints Scott Coiante as CFO
Board/Management Information Classification · 1% confidence The document is a press release announcing the appointment of a new Chief Financial Officer (Scott Coiante) at a portfolio company (Aprea Therapeutics). According to the filing definitions, announcements regarding changes in senior management fall under the 'MANG' category. Although the document includes an 'Attachment' link, the primary content is the announcement of the management change itself, not merely a notification of a report publication.
2019-08-05 English
Karolinska Development's portfolio company Aprea Therapeutics appoints Scott Coiante as CFO
Board/Management Information Classification · 1% confidence The document is a press release announcing the appointment of a new Chief Financial Officer (Scott Coiante) at a portfolio company (Aprea Therapeutics). According to the filing definitions, announcements regarding changes in senior management fall under the 'MANG' category. Although the document includes an 'Attachment' link, the primary content is the announcement of the management change itself, not merely a notification of a report publication.
2019-08-05 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.